One in three American adults has it. Most feel nothing. Standard tests often miss it. And the consequences reach far beyond the liver itself.
Fatty liver disease — now formally called Metabolic dysfunction-Associated Steatotic Liver Disease, or MASLD — occurs when excess fat accumulates in liver cells beyond what the liver can safely process.
But calling it a "liver problem" undersells what is actually happening. The liver is not a passive storage site. It is one of the most metabolically active organs in the body, managing lipid metabolism, glucose regulation, inflammatory signaling, hormonal clearance, and protein synthesis simultaneously. When it becomes overloaded with fat, these systems begin to malfunction — not just within the liver, but across the cardiovascular, metabolic, and endocrine systems it serves.
This is why research consistently shows that people with fatty liver face approximately twice the cardiovascular event risk of those without it — even when the liver itself has not yet progressed to advanced disease. The liver's dysfunction becomes the body's dysfunction.
You may have seen several names for this condition. Nonalcoholic fatty liver disease (NAFLD) was the original term used for decades. In 2023, a global expert consensus renamed it MASLD — Metabolic dysfunction-Associated Steatotic Liver Disease — to better reflect its metabolic origins and remove the stigmatizing "nonalcoholic" framing.
NASH (nonalcoholic steatohepatitis) referred to the inflamed, more advanced form of NAFLD. The updated term is MASH — metabolic dysfunction-associated steatohepatitis. Throughout this site, we use MASLD and fatty liver disease interchangeably.
Understanding why fatty liver matters requires understanding what the liver actually does. It is far more than a detox organ. Its metabolic functions are deeply intertwined with your cardiovascular and hormonal health — which is why liver dysfunction sends ripples through every system it touches.
The liver manufactures, packages, and clears lipoproteins including LDL, HDL, and triglycerides. In fatty liver, this process becomes dysregulated, producing a pattern of elevated triglycerides, elevated small dense LDL, and reduced HDL — an atherogenic lipid profile that directly drives cardiovascular risk.
The liver is the primary site of glucose storage and release. In fatty liver, hepatic insulin resistance causes the liver to release excess glucose even in a fed state, contributing to elevated fasting glucose, impaired glucose tolerance, and progression toward type 2 diabetes.
A fat-laden liver generates chronic low-grade inflammation through elevated hs-CRP, TNF-alpha, and IL-6 production. This systemic inflammatory state promotes endothelial dysfunction and accelerates atherosclerotic plaque development — connecting liver health directly to heart disease risk.
The liver clears and metabolizes estrogens, thyroid hormones, cortisol, and insulin. When hepatic function is compromised by fat accumulation, hormonal clearance slows — contributing to estrogen dominance, altered thyroid conversion, and cortisol dysregulation that compound metabolic dysfunction.
Fatty liver exists on a spectrum. Most people are identified at early stages — or not identified at all until the disease has advanced. Understanding the stages clarifies why early detection matters so much.
The critical point: fibrosis stage, not fat content alone, is the strongest predictor of long-term outcomes. But by the time fibrosis is detectable by standard imaging, the early intervention window has often passed.
Fat accumulates in liver cells with minimal inflammation or cell damage. No symptoms. Standard enzyme tests are often normal. This is the most reversible stage — and the one most commonly missed.
Highly reversibleFat accumulation now accompanied by hepatocellular inflammation and injury. Liver enzymes may begin to elevate. Cardiovascular risk is significantly amplified at this stage.
Reversible with interventionChronic inflammation triggers scarring of liver tissue. Early fibrosis can still be partially reversed with the right approach. Advanced fibrosis becomes the strongest independent predictor of liver-related and cardiovascular mortality.
Partially reversibleExtensive scarring replaces functional liver tissue. At this stage, liver function is permanently compromised. Mortality risk from liver disease, cardiovascular disease, and cancer is substantially elevated.
Limited reversibilityFatty liver is strongly associated with metabolic syndrome — but it is not exclusive to it. A significant proportion of people with fatty liver are of normal weight, have normal glucose, and carry no single obvious risk factor. The condition develops from the convergence of multiple subclinical metabolic stressors, not one single cause.
This is precisely why single-marker screening misses so many cases. No one risk factor tells the complete story. The pattern matters more than any individual value.
Standard liver enzyme tests were not designed to screen for fatty liver. Imaging misses early-stage disease. And risk accumulates across systems that standard panels don't assess together. The detection gap is real — and it's fixable.
1. Issa G, Shang Y, Strandberg R, Hagström H, Wester A. Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden. J Hepatol. 2025;83:643–651.
2. Zhong J, Zhao Y, He H, Lan Y, Cai Z. Risk-associated and clinically informative biomarkers for cardiovascular risk stratification in metabolic dysfunction-associated steatotic liver disease. Am J Prev Cardiol. 2026;26:101415.
3. NASH Clinical Research Network. Prevalence of normal ALT in biopsy-proven NAFLD. Referenced in multiple NCS publications on noninvasive screening limitations.